Buy SUNEKOS® BODY Online

Product Description

Sunekos® Body Product Overview

Sunekos® Body is an injectable biorestructuring treatment specifically formulated for treating stretch marks and skin laxity in the body. Utilizing a patented blend of low-density hyaluronic acid (HA) and amino acids (HY6AA formula), Sunekos® Body is designed to promote collagen and elastin production, stimulating extracellular matrix (ECM) regeneration. It addresses challenging areas with compromised skin elasticity, such as the arms, inner thighs, knees, and abdomen. This non-surgical treatment option is especially suitable for patients seeking gradual, natural-looking improvements in skin texture and firmness​.

Key Features:

• Hyaluronic Acid and Amino Acid Complex: Contains glycine, L-proline, L-lysine, L-leucine, L-valine, and L-alanine.
• Target Areas: Arms, inner thighs, knees, abdomen, and other areas affected by skin laxity and stretch marks.
• Administration: Injectable, delivered directly into the dermis for targeted biostimulation and biorestructuring.

Sunekos® Body Indications for Use

Sunekos® Body is indicated for treating skin laxity and stretch marks (striae distensae) on various body areas. This treatment’s bio-stimulating formula promotes collagen and elastin production to help restore firmness and elasticity in sagging or lax skin. Its amino acid profile specifically targets ECM components, making it ideal for patients with age-related skin laxity or post-pregnancy stretch marks.

Primary Indications:

• Stretch Marks: Targets both early (Rubra) and mature (Alba) stretch marks, minimizing their visibility.
• Skin Laxity: Improves firmness and tone in areas affected by sagging or compromised elasticity.
• General Skin Biorestructuring: Ideal for enhancing overall skin texture and resilience, particularly in areas prone to aging and stretching​.

Sunekos® Body Dosage Information

The Sunekos® Body treatment requires specific dosages and techniques tailored to each target area and the severity of the skin concern. The recommended protocol includes microinjections or cannula applications at varied depths in the dermis.

Treatment Protocols for Key Areas:

1. Stretch Marks:
   • Injection Technique: 30-32G needle, 12-13mm, using a micro-bolus approach at three depths (superficial, medium, and deep dermis).
   • Volume: 0.2 ml per bolus, with the number of injections based on the size of the stretch mark.
   • Frequency: 3-4 sessions, spaced every 15 days.
2. Skin Laxity (e.g., Arms, Thighs, Abdomen):
   • Arms: 2.5 to 5 ml per arm, using a cannula (0.3 ml per point, 1-2 areas per arm).
   • Inner Thigh and Knee: 5 ml per part, with injections at 10 ml per side, depending on laxity.
   • Abdomen: 10 ml in total, divided into upper and lower parts, administered via cannula (1 ml per point).
   • Frequency: 3 sessions per area, spaced every 15-21 days​.

Sunekos® Body Side Effects and Precautions

Sunekos® Body is formulated to be biocompatible, minimizing risks of severe reactions. However, patients may experience minor side effects typical of injectable treatments.

Common Side Effects:

• Redness and Swelling: Temporary swelling or redness at injection sites, which typically resolves within 1-3 days.
• Bruising: Minor bruising may occur, especially in sensitive areas or for patients prone to bruising.
• Discomfort or Tenderness: Some patients may feel mild discomfort post-injection, which generally subsides quickly.

Precautions:

• Sterile Technique: Ensure proper aseptic conditions to reduce infection risks.
• Contraindications: Not recommended for patients with autoimmune disorders, active skin infections, or hypersensitivity to HA or amino acids.
• Pregnancy and Breastfeeding: Usage is not recommended during pregnancy or breastfeeding due to insufficient safety data.
• Post-Treatment Care: Patients are advised to avoid intense physical activity and direct sun exposure for 24-48 hours post-treatment to prevent irritation​.

Sunekos® Body Clinical Studies or Real-World Outcomes

Sunekos® Body has demonstrated efficacy in clinical studies, showing improvements in skin elasticity and texture with a high level of patient satisfaction. Clinical outcomes have been observed through photographic scales and profilometry measures, confirming visible and measurable skin improvement.

Key Findings:

• Skin Laxity Reduction: Studies involving 21 patients showed a visual score reduction of 15-30% in skin laxity after four sessions.
• Stretch Mark Improvement: Patients treated for stretch marks observed visible reductions in stretch mark depth and width, particularly when targeting early-stage (Rubra) marks.
• Long-Term Results: Significant improvements were noted at 2 and 4 months post-initial treatments, with a sustained reduction in skin laxity and enhanced skin density.

Clinical Observations:

• A study measured skin roughness and density improvements in patients with sagging skin on the inner arms and thighs, with 22-32% reductions in skin roughness after regular Sunekos® Body applications.
• Patients treated on the abdomen and inner knee displayed smoother skin profiles, as measured by the Primos Compact portable equipment​.

Sunekos® Body Composition and Active Ingredients

Sunekos® Body contains a specialized blend of low-density hyaluronic acid and a patented HY6AA amino acid formula, designed to target specific skin needs in the body’s ECM. This combination supports collagen IV and elastin synthesis for deep tissue regeneration.

Key Ingredients:

• Hyaluronic Acid: Provides hydration and volume, enhancing skin elasticity and supporting collagen structure.
• Amino Acid Complex: Includes glycine, L-proline, L-lysine, L-leucine, L-valine, and L-alanine, all crucial for collagen and elastin synthesis within the ECM.
• Adapted Electrolyte Composition: The formula mirrors the electrolyte balance in the interstitial fluids of the body, optimizing compatibility and reducing irritation​.

Sunekos® Body Drug Interactions

Sunekos® Body is generally safe and poses minimal risk of drug interactions due to its localized administration. However, certain considerations apply.

Important Considerations:

Caution with Immunosuppressants: Use carefully with patients on immunosuppressive therapy, as they may have a higher risk of infection​.

Combination Treatments: Can be used alongside other biostimulatory treatments, though spacing by at least two weeks is recommended.

Anticoagulants: Patients on blood-thinning medications should be advised of the increased risk of bruising at injection sites.